Who is sponsoring NCT01243307?

NCT01243307 is sponsored by Creabilis SA.

What drugs are being tested in NCT01243307?

Interventions in NCT01243307: CT327 (or placebo) followed by placebo (or CT327).

What condition does NCT01243307 study?

NCT01243307 studies Neuropathic Pain.

Is NCT01243307 still recruiting?

NCT01243307 is currently completed. Last updated 6 June 2011.

Last reviewed 2011-06-06 · How we verify

NCT01243307

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I, Single-centre, Multiple-dose, Placebo-controlled Crossover Study to Investigate the Pharmacodynamic Effects of CT327 (0.1% Topical Cream) on Intra-dermal Nerve Growth Factor (NGF) and Evoked Pain Responses, in Healthy Male Volunteers

Completed Phase 1 Last updated 6 June 2011

What this trial tests

Phase 1 trial testing CT327 (or placebo) followed by placebo (or CT327) in Neuropathic Pain in 24 participants. Completed in 1 May 2011.

Timeline

1 January 2011

Primary endpoint
1 April 2011

1 May 2011

Quick facts

Lead sponsor	Creabilis SA
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	basic science
Enrollment	24
Start date	1 January 2011
Primary completion	1 April 2011
Estimated completion	1 May 2011
Sites	1 location across Denmark

Drugs / interventions tested

CT327 (or placebo) followed by placebo (or CT327) — full drug profile →

Conditions studied

Neuropathic Pain — all drugs for Neuropathic Pain →

Sponsor

Creabilis SA — full company profile →

Who can join

Adults 18 to 64, male only, with Neuropathic Pain. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

An alteration in the peripheral sensitisation after treatment with CT327
Time frame: 2 treatment/testing periods each lasting 4 days and separated by at least 10 days

Sponsor's own description

The primary objective of this study is to compare the effect of CT327 to placebo against experimental induced superficial, deep and hyperalgesic pain. The secondary objectives are to elucidate the mechanisms of CT327 using experimental pain models.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Neuropathic Pain

Currently open trials in the same condition.

NCT07493213 — USG-Guided Shoulder Injections in Frozen Shoulder · NA · recruiting
NCT07493226 — Efficacy of Chemically Distinct Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Pain Phenotypes in Adhesive Capsulitis · NA · recruiting
NCT06398847 — Virtual Reality (VR) Self-Hypnosis Software · NA · recruiting
NCT07487610 — Relationship Between Neuropathic Pain and Geriatric Assessment Parameters in Patients Aged 80 Years and Older · recruiting
NCT07436806 — SPS Block vs. Surgical Intercostal Block for Chronic Pain After Thoracoscopic Surgery · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01243307 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Creabilis SA
Last refreshed: 6 June 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01243307.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing